Executive Director, Portfolio Management

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$265K-$331K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$102,662 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.4% - Faster than average

190% above the BLS role benchmark for product management aggregate.

Matched to SOC 11-1021 - Product Management aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Product From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Executive Director, Portfolio Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are looking for a highly motivated individual with experience in portfolio management, decision analysis and a passion for developing solutions for complex problems to build out this cross-functional capability and help shape our portfolio strategy. This position will report to the SVP, Development Management and Program Leadership and will be based at our headquarters in Redwood City, CA. In this highly cross functional role, you will be expected to evolve the wider portfolio management capability within Revolution Medicines and closely collaborate with Portfolio Working Group, Disease Area Teams, Program Teams, Life Cycle Teams, Analytics and Insights, Finance, Commercial and many other relevant functions. You must be entrepreneurial, able to “roll up their sleeves” and thrive in a fast-paced, highly cross-functional environment. You are an exceptional strategic and critical thinker, have a passion for interpreting and analyzing complex data, and have strong interpersonal

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.